Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial

Introduction Targeted immunomodulators (eg, advanced therapies) effectively achieve symptomatic remission in patients with inflammatory bowel disease (IBD). However, ~25%–50% of patients with IBD achieving symptomatic remission with an advanced therapy may have continued endoscopically/radiologicall...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Sagar Patel, Vipul Jairath, Guangyong Zou, Jeffrey D McCurdy, Greg Rosenfeld, Christopher Ma, Frank Hoentjen, Talat Bessissow, David T Rubin, Corey A Siegel, Gil Y Melmed, Ashwin N Ananthakrishnan, Ann D Flynn, Neeraj Narula, Caroline Hwang, Siddharth Singh, Tauseef Ali, Jasmine D Nguyen, David I Fudman, Mark E Gerich, Samir A Shah, David Hudesman, Ryan A McConnell, Dana J Lukin, Brandon Sprung, Jill K J Gaidos, Mark C Mattar, Jana G Hashash, Mark Metwally, Raymond K Cross, Jorge R Rodriguez Gaytan, Emily-Sophinie Gurrola, S Alandra Weaver, Sydney Power, Jason K Hou
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMJ Publishing Group 2025-07-01
Rangatū:	BMJ Open Gastroenterology
Urunga tuihono:	https://bmjopengastro.bmj.com/content/12/1/e001615.full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!